Page 3 - Dr Reddy’s

Dr Reddy's, Natco Pharma launch generic cancer drug in Canada

Dr Reddy's Laboratories and Natco Pharma on Thursday said they have launched generic capsules used in the treatment of multiple myeloma and myelodysplastic syndrome patients in the Canadian market.

DRL seeks a booster from Sputnik V but hurdles in scaling up remain

Even as the company investigates complaints of malpractice in the Ukraine, hurdles in scaling up the Russian vaccine remain the bigger challenge in the near term

Dr Reddy's to sell US, Canada territory rights for migraine drug to BDSI

Drug firm Dr Reddy's Laboratories on Wednesday said it has entered into a definitive agreement with BioDelivery Sciences International, Inc., to sell its US and Canada territory rights

DRL stock falls 10% after missing Q1 estimates, probe by US SEC

The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22

Covid-19 pandemic: Sputnik V vaccine imports likely to improve from August

Trials on adolescents in Russia expected to end by October: DRL

Indian pharma industry to touch $130 bn by 2030: Dr Reddy's chairman

The Indian pharmaceutical industry is expected to grow almost by three times to about 130 billion US dollars by 2030

Sputnik V second dose shortage to delay India's full rollout: Dr Reddy's

Dr. Reddy's had received about 3 million first doses by June 1 and about 360,000 doses of the second by early this month, the company and the Indian government have said

Shilpa Medicare arm inks pact with Dr Reddy's to manufacture Sputnik V vax

Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy's Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V. "The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added. Shilpa Medicare said Dr Reddy's will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy's is responsible for distribution/marketing of the vaccine in its ...

Dr Reddy's to get 36 mn doses of Sputnik V vaccine in next few months

The drugmaker on Friday reported a 27.6% drop in fourth-quarter consolidated net profit, compared with a year earlier.

Dr Reddy's receives DCGI approval for restricted emergency use of Sputnik V

Drug major Dr Reddy's Laboratories on Tuesday said it has received approval from Indian drug regulator for restricted emergency use of Covid-19 vaccine Sputnik V in the country

India approves Sputnik V vaccine, to produce 850 mn doses annually: RDIF

The RDIF has said that India has become the 60th country to approve the use of Sputnik V against coronavirus

Dr Reddy's to submit more data on Covid-19 vaccine Sputnik V by July

Colour-coded doses will have two different antigens

Dr Reddy s eyes to launch Sputnik V vaccine for Covid-19 under EUA in March

Dr Reddys Laboratories (DRL) on Friday said it expected Russia's COVID-19 vaccine Sputnik V to be launched in India through Emergency Use Authorisation (EUA) by March this year.

Dr Reddy's seeks nod from Canada for Favipiravir pills for Covid treatment

Dr Reddy's Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate Covid-19 adult patients

DRL, RDIF commence clinical trials for Sputnik V Covid-19 vaccine in India

Dr Reddy's Laboratories and Russian Direct Investment Fund (RDIF) on Tuesday said they have commenced adaptive phase 2/3 clinical trials for the Sputnik V COVID-19 vaccine in India. The trials have commenced after receiving the necessary clearance from the Kasauli-based Central Drugs Laboratory, they added. This will be a multicentre and randomised controlled study, which will include safety and immunogenicity study, the Hyderabad-based drug maker and RDIF said in a joint statement. The clinical trials are being conducted by JSS Medical Research as the clinical research partner. Further, Dr Reddy's has partnered with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT) for advisory support and to use BIRAC's clinical trial centres for the vaccine, it added. Recently, RDIF had announced the second interim analysis of clinical trial data, which showed 91.4 per cent efficacy for the vaccine on day 28 after the first dose; and efficacy of o

Analysts slash FY22 profit estimates; telecom, PSU banking firms suffer

An analysis done by Motilal Oswal Financial Services (MOFSL) shows, health care and technology are the only two sectors which have seen an upgrade in FY22 earnings

Healthy growth in India, US helps Dr Reddy's post strong Q2 performance

Wockhardt buy, Covid portfolio aid India business growth

Covid-19: Dr Reddy's engages Indian partners to develop Sputnik V

Sputnik V is also undergoing Phase 3 clinical trials in Russia and other parts of the globe on 40,000 volunteers

Dr Reddy's Laboratories shuts all units after cyber attack on servers

Security breach comes days after firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V

Dr Reddy's gets nod for 2/3 vaccine trial; Key updates about the virus

A PMO release said three vaccines are in advanced stages of development in India, out of which two are in Phase II and one is in Phase-III